-
1.发明申请公开(公告)号：US20070154955A1
公开(公告)日：2007-07-05
申请号：US11320665
申请日：2005-12-30
Applicant: Tzu-Ling Tseng , Ping-Fu Cheng , Shyh-Shin Chiou
Inventor： Tzu-Ling Tseng , Ping-Fu Cheng , Shyh-Shin Chiou
IPC: G01N33/567 , G01N33/53
CPC classification number: G01N33/564 , G01N33/6854 , G01N2800/04
Abstract: A method of diagnosing autoimmune polyglandular syndrome (APS) in a subject, and a kit for identifying a subject having autoimmune polyglandular syndrome (APS) are provided.
Abstract translation: 本发明提供一种诊断受试者自身免疫多腺综合征（APS）的方法，以及用于鉴定具有自身免疫性多腺综合征（APS）的受试者的试剂盒。
-
公开(公告)号：US20050136489A1
公开(公告)日：2005-06-23
申请号：US11013684
申请日：2004-12-17
Applicant: Tzu-Ling Tseng , Ping-Fu Cheng
Inventor： Tzu-Ling Tseng , Ping-Fu Cheng
IPC: G01N33/53 , C07K14/47 , C07K16/18 , G01N21/78 , G01N33/543 , G01N33/567 , G01N33/574 , G01N33/68
CPC classification number: G01N33/57438 , G01N33/6893 , G01N2800/08 , G01N2800/085
Abstract: Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity.
Abstract translation: 提供肝脏疾病的生物标志物及其使用方法。 为了检测肝硬化和肝癌，生物标志物选自SEQ ID NO：1至SEQ ID NO：24的任一氨基酸序列或衍生物或片段或变体或其组合或针对氨基酸序列的抗体 。 然后生物标志物进一步发展为检测试剂盒，通过检测筛选标本中自身抗体或自身抗原的存在，以更高的准确度和灵敏度检测肝脏疾病。
-
公开(公告)号：US08476077B2
公开(公告)日：2013-07-02
申请号：US12969039
申请日：2010-12-15
Applicant: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
Inventor： Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
CPC classification number: G01N33/6893 , G01N2333/4728 , G01N2333/52 , G01N2333/71 , G01N2333/8125 , G01N2800/347 , G01N2800/52 , G01N2800/56
Abstract: Disclosed is use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
Abstract translation: 公开了使用尿液和血清生物标志物诊断糖尿病肾病，分期糖尿病肾病，监测糖尿病肾病进展和评估糖尿病肾病治疗效果。 这些生物标志物包括尿前体α-2-HS-糖蛋白，尿α-1抗胰蛋白酶，尿α-1酸糖蛋白，尿骨桥蛋白，血清骨桥蛋白，其片段及其组合。
-
公开(公告)号：US20100136579A1
公开(公告)日：2010-06-03
申请号：US12628758
申请日：2009-12-01
Applicant: Tzu-Ling Tseng , Hung-Yi Li , Yen-Peng Li , Angelina Huai-Lo Lee , Yi-Chen Liu , Ping-Fu Cheng , Wei-Ya Lin , Hong-Zen Yeh
Inventor： Tzu-Ling Tseng , Hung-Yi Li , Yen-Peng Li , Angelina Huai-Lo Lee , Yi-Chen Liu , Ping-Fu Cheng , Wei-Ya Lin , Hong-Zen Yeh
IPC: G01N33/573 , C12Q1/52 , C12Q1/37
CPC classification number: G01N33/6893 , G01N33/487 , G01N33/49 , G01N33/50 , G01N33/5067 , G01N33/53 , G01N33/576 , G01N2333/70539 , G01N2333/96494 , G01N2333/9723 , G01N2800/085
Abstract: Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.
Abstract translation: 鉴定尿激酶型纤溶酶原，基质金属蛋白酶9和＆bgr.2-微球蛋白作为与肝纤维化相关的新型生物标志物及其在诊断肝纤维化中的用途。
-
公开(公告)号：US20080241863A1
公开(公告)日：2008-10-02
申请号：US12073603
申请日：2008-03-07
Applicant: Tzu-Ling Tseng , Ping-Fu Cheng
Inventor： Tzu-Ling Tseng , Ping-Fu Cheng
IPC: G01N33/53
CPC classification number: G01N33/57438 , G01N33/6893 , G01N2800/08 , G01N2800/085
Abstract: Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity.
Abstract translation: 提供肝脏疾病的生物标志物及其使用方法。 为了检测肝硬化和肝癌，生物标志物选自SEQ ID NO：1至SEQ ID NO：24的任一氨基酸序列或衍生物或片段或变体或其组合或针对氨基酸序列的抗体 。 然后生物标志物进一步发展为检测试剂盒，通过检测筛选标本中自身抗体或自身抗原的存在，以更高的准确度和灵敏度检测肝脏疾病。
-
Patent Agency Ranking
公开(公告)号：US20100197033A1
公开(公告)日：2010-08-05
申请号：US12694575
申请日：2010-01-27
Applicant: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
Inventor： Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
IPC: G01N33/48
CPC classification number: G01N33/6893 , G01N2333/4728 , G01N2333/52 , G01N2333/71 , G01N2333/8125 , G01N2800/347 , G01N2800/52 , G01N2800/56
Abstract: Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
Abstract translation: 使用尿液和血清生物标志物诊断糖尿病肾病，分期糖尿病肾病，监测糖尿病肾病进展，评估糖尿病肾病治疗效果。 这些生物标志物包括尿前体α-2-HS-糖蛋白，尿α-1抗胰蛋白酶，尿α-1酸糖蛋白，尿骨桥蛋白，血清骨桥蛋白，其片段及其组合。
-
公开(公告)号：US20100261209A1
公开(公告)日：2010-10-14
申请号：US12763453
申请日：2010-04-20
Applicant: Tzu-Ling TSENG , Ping-Fu Cheng
Inventor： Tzu-Ling TSENG , Ping-Fu Cheng
IPC: G01N33/53
CPC classification number: G01N33/57438 , G01N33/6893 , G01N2800/08 , G01N2800/085
Abstract: Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity.
Abstract translation: 提供肝脏疾病的生物标志物及其使用方法。 为了检测肝硬化和肝癌，生物标志物选自SEQ ID NO：1至SEQ ID NO：24的任一氨基酸序列或衍生物或片段或变体或其组合或针对氨基酸序列的抗体 。 然后生物标志物进一步发展为检测试剂盒，通过检测筛选标本中自身抗体或自身抗原的存在，以更高的准确度和灵敏度检测肝脏疾病。
-
公开(公告)号：US07807378B2
公开(公告)日：2010-10-05
申请号：US11321516
申请日：2005-12-29
Applicant: Tzu-Ling Tseng , Pei-Hsiu Liao , Ping-Fu Cheng , Shih-Feng Tsai , Hou-Chang Chiu
Inventor： Tzu-Ling Tseng , Pei-Hsiu Liao , Ping-Fu Cheng , Shih-Feng Tsai , Hou-Chang Chiu
IPC: G01N33/53
CPC classification number: G01N33/564 , G01N33/6854 , G01N2800/10 , G01N2800/28 , G01N2800/2835 , Y10S436/811
Abstract: The present invention relates to methods of diagnosing myasthenia gravis in a subject, by determining an amount of at least one autoantibody that specifically binds one or more autoantigens selected from heat-shock protein 60 (hsp60), heat-shock protein 90, alpha isoform (hsp90α), and heat-shock protein 90, beta isoform (hsp90β). The invention also provides diagnostic kits for identifying a subject having myasthenia gravis.
Abstract translation: 本发明涉及通过确定特异性结合一种或多种选自热休克蛋白60（hsp60），热休克蛋白90，α同工型（hsp60）的自身抗原的至少一种自身抗体的量来诊断受试者的重症肌无力的方法 hsp90α）和热休克蛋白90，β异构体（hsp90和bgr）。 本发明还提供了用于鉴定重症肌无力的受试者的诊断试剂盒。
-
9.发明申请Method for Diagnosing Membranous Glomerulonephritis Disease and a Kit Thereof 审中-公开诊断膜性肾小球肾炎的方法及其试剂盒公开(公告)号：US20080166741A1
公开(公告)日：2008-07-10
申请号：US11620064
申请日：2007-01-05
Applicant: Tzu-Ling Tseng , Pei-Hsiu Liao , Ping-Fu Cheng , Chi-Hung Cheng
Inventor： Tzu-Ling Tseng , Pei-Hsiu Liao , Ping-Fu Cheng , Chi-Hung Cheng
CPC classification number: G01N33/564 , G01N2800/347
Abstract: Some specific autoantigens of MGN are discovered by using the integrated platform. Moreover, according to the specificity between antibodies and antigens, a method for diagnosing MGN are constructed. This diagnostic method is cooperated with ELISA, RIA, immunofluorescence, or other immunochromatography techniques. Finally, a diagnostic kit is provided to implement the method above.
Abstract translation: 通过使用集成平台发现MGN的一些特定自身抗原。 此外，根据抗体和抗原的特异性，构建了用于诊断MGN的方法。 该诊断方法与ELISA，RIA，免疫荧光或其他免疫色谱技术相结合。 最后，提供诊断套件来实现上述方法。
-
公开(公告)号：US08465980B2
公开(公告)日：2013-06-18
申请号：US12694575
申请日：2010-01-27
Applicant: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
Inventor： Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
CPC classification number: G01N33/6893 , G01N2333/4728 , G01N2333/52 , G01N2333/71 , G01N2333/8125 , G01N2800/347 , G01N2800/52 , G01N2800/56
Abstract: Disclosed is use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.027 seconds)
